William Blair analyst Brandon Vazquez has maintained their bullish stance on ELAN stock, giving a Buy rating on October 30.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Vazquez has given his Buy rating due to a combination of factors including Elanco Animal Health’s strong performance in the U.S. farm animal segment, which significantly exceeded expectations. This outperformance contributed to sales and earnings per share surpassing consensus estimates by 4% and $0.06, respectively.
Furthermore, the company’s broad portfolio of innovative products is gaining traction, supporting increased sales and profitability. The management’s guidance has been raised, and the balance sheet is being deleveraged, reinforcing the positive outlook. With shares trading at 23 times the projected 2026 earnings per share, Vazquez maintains an optimistic view, anticipating that an improving profit and loss statement will drive further share price appreciation.
In another report released on October 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $23.00 price target.